|
Impact of different patient diseases on authorized generic change
|
|
| Author:
|
ATSUSHI ISHIMURA, MAYUMI TOMIZAKI
|
| Abstract:
|
Aging is a global challenge, with rapid progress in both developed and developing countries. Healthcare costs continue to increase, and many countries are pursuing policies to reduce them through cheaper generic
equivalent (GE) medicines. In the USA, there is an authorized generic (AG) system under which a GE identical to an original drug can be launched with a patent license of the original drug. AG has recently been introduced
in Japan, and its use is expected to be promoted to reduce medical costs. Previously, we conducted a survey on AG modification for those wishing to use original medicines and found that modification was possible in 50% of patients. However, there has been no research on whether different diseases affect AG changes; therefore, we conducted a survey on AG changes using two medicines with different indications. Patients who were prescribed amlodipine (for hypertension) or rosuvastatin (for hypercholesterolemia) at an insurance
pharmacy were included, and the number and age of patients requesting the original drug and AG were compared. The results showed no difference in the age or proportion of patients who preferred the original drug; however, those who preferred the original drug but could change if it was an AG were more likely to be on amlodipine, suggesting that different diseases may lead to differences in the selectivity for AGs. In addition to being an AG, the reason for this could be that the drug names of the original and generic drugs were
similar.
|
| Keyword:
|
Authorized generics, Generic medicines, Aging population, Healthcare costs
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2024.16.03.002
|
| Download:
|
Request For Article
|
|
|